Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study

Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study

Abstract ChulaCov19 mRNA vaccine demonstrated promising phase 1 results. Healthy adults aged 18–59 years were double-blind randomised 4:1 to receive two intramuscular doses of ChulaCov19 50 µg or placebo. Primary endpoints were safety and microneutralization antibody against-wild-type (Micro-VNT50)...

Full description

Bibliographic Details
Main Authors: Thanyawee Puthanakit, Eakachai Prompetchara, Sivaporn Gatechompol, Chutitorn Ketloy, Arunee Thitithanyanont, Anan Jongkaewwattana, Supranee Buranapraditkun, Sasiwimol Ubolyam, Stephen J. Kerr, Jiratchaya Sophonphan, Tanakorn Apornpong, Wonngarm Kittanamongkolchai, Sarawut Siwamogsatham, Somchai Sriplienchan, Kanitha Patarakul, Tuangtip Theerawit, Pathariya Promsena, Rapisa Nantanee, Siwaporn Manomaisantiphap, Sarun Chokyakorn, Lina Hong, Mijo Samija, David C. Montefiori, Hongmei Gao, Amanda Eaton, Wassana Wijagkanalan, Mohamad-Gabriel Alameh, Drew Weissman, Kiat Ruxrungtham, ChulaVac001-Phase 2 study team
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-49653-6

Internet

https://doi.org/10.1038/s41598-023-49653-6

Similar Items